# JLMediLabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jlmedilabs

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.jlmedilabs.com
- Latest round: Seed (Mar 1, 2019)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2018 by CEO Lee Jong-Jin, JLMediLabs is a medical technology company that develops technologies to detect and diagnose health issues by using blood droplets. The company manufactures high-sensitivity biomarker-based diagnostic and detection kits by fusing single-molecule fluorescence and ultra-high-resolution fluorescence microscopy technology. In August 2022, JLMediLabs raised KRW 3.4 billion in pre-series A funding from HYU Holdings, PathfinderH, Primer, Primer Sazze Partners, and Seoul Technology Holdings.

The company provides early diagnostic and detection kits that require a drop of blood by harnessing single-molecule techniques.

JLMediLabs plans to use its proceeds from August 2022 funding to conduct clinical trials, automate production, and improve its biomarker utilization technology. The company also plans to use 10-20 biomarkers for each carcinoma to advance the technology for enabling accurate diagnosis compared to existing ones and to conduct clinical trials together.

## Funding rounds

- Seed, Mar 1, 2019 — Korea Tech Incubator for Startup, Ulsan Creative Economy Innovation Center

## Investors

- Korea Tech Incubator for Startup — Seed
- Ulsan Creative Economy Innovation Center (https://capitalatlas.ai/funds/ulsan-creative-economy-innovation-center) — Seed